洞察
Insights From Our Experts
Articles
Pathways for Paying for Rare Disease Treatments
Posted by
Dr. Richard Stefanacci on 5月 13, 20195/13/19
This article was written for the Journal of Clinical Pathways Determining how to pay for the treatment of uncommon yet serious diseases is an important consideration in terms of sustainability and patient access. Novel and expensive…
Care pathways—do you know where your biosimilars are used?
Posted on 4月 25, 20194/25/19
Biological therapies are often very expensive, putting pressure on healthcare budgets that are already restricted and potentially resulting in a decrease in patient access to treatment, in Europe biosimilar versions have been eagerly awaited in many…
‘Tis the season for pharma in China, as the government expedites uptake of new urgently needed drugs
PRICENTRIC BRIEF: Universal health insurance coverage for 1.3 billion people means China must increase uptake of “clinically urgently needed new drugs” already approved in the US, EU, and Japan Mostly oncology products are being imported, along…
“Who wants the biggest slice of the biosimilar pie?”: The Humira biosimilar wave in Europe
PRICENTRIC BRIEF: Biosimilar competition in Europe has brought about discounts to AbbVie’s blockbuster immunosuppressant drug Humira upwards of 80% during tendering Overall, biosimilar uptake has increased in Europe because biologic “copycats” are cheaper, but full faith…
Medicare & Medicaid: A Rollback on Rebates
In January 2019, the Department of Health and Human Services (HHS) put forth a proposed rule to repeal the safe harbor status for Medicare and Medicaid drug rebates under the Anti-Kickback statute. This idea was first…
Wearables In Clinical Trials
Pharma Voice Magazine features Sandra Shpilberg from Seeker Health, an EVERSANA company, in their March 2019 issue. The topic is “Wearables in Clinical Trial”. The article discusses how wearables are improving the clinical trial experience for patients…